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is the immediate precursor of D-serine, a major agonist of the
N-methyl-D-aspartate (NMDA) receptor. L-Serine is a pivotal amino acid since it
serves as a precursor to a large number of essential metabolites besides D-serine.
In all non-photosynthetic organisms, including mammals, a major source of L-serine
is the phosphorylated pathway of L-serine biosynthesis. The pathway consists of
three enzymes, D-3-phosphoglycerate dehydrogenase (PGDH), phosphoserine amino
transferase (PSAT), and L-phosphoserine phosphatase (PSP). PGDH catalyzes the first
step in the pathway by converting D-3-phosphoglycerate (PGA), an intermediate in
glycolysis, to phosphohydroxypyruvate (PHP) concomitant with the reduction of NAD+ .
In some, but not all organisms, the catalytic activity of PGDH can be regulated by
feedback inhibition by L-serine. Three types of PGDH can be distinguished based on
their domain structure. Type III PGDHs contain only a nucleotide binding and substrate
binding domain. Type II PGDHs contain an additional regulatory domain (ACT domain),
and Type I PGDHs contain a fourth domain, termed the ASB domain. There is no
consistent pattern of domain content that correlates with organism type, and even when
additional domains are present, they are not always functional. PGDH deficiency results
in metabolic defects of the nervous system whose systems range from microcephaly
at birth, seizures, and psychomotor retardation. Although deficiency of any of the
pathway enzymes have similar outcomes, PGDH deficiency is predominant. Dietary
or intravenous supplementation with L-serine is effective in controlling seizures but
has little effect on psychomotor development. An increase in PGDH levels, due to
overexpression, is also associated with a wide array of cancers. In culture, PGDH is
required for tumor cell proliferation, but extracellular L-serine is not able to support cell
proliferation. This has led to the hypothesis that the pathway is performing some function
related to tumor growth other than supplying L-serine. The most well-studied PGDHs
are bacterial, primarily from Escherichia coli and Mycobacterium tuberculosis, perhaps
because they have been of most interest mechanistically. However, the relatively recent
association of PGDH with neuronal defects and human cancers has provoked renewed
interest in human PGDH.
Keywords: D-serine, L-serine, phosphoglycerate, dehydrogenase, biosynthesis
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INTRODUCTION

many other metabolites, L-serine, particularly when present at
high levels, can also be converted into pyruvate and ammonia
by L-serine dehydratase (LSD). The glycolytic precursor of Lserine, PGA can be generated from glucose by glycolysis or
from pyruvate by an abbreviated gluconeogenesis pathway that
produces phosphoenolpyruvate and then PGA. In E. coli, ∼15%
of the carbon assimilated when it is grown on glucose passes
through L-serine before incorporation into biosynthetic products
(Pizer and Potochny, 1964). In humans, ∼75% of the L-serine
that appears during fasting comes from de novo serine synthesis
(Kalhan and Hanson, 2012). In mammals, under normal dietary
conditions, most of the L-serine is synthesized in the kidney.
However, when dietary protein is limiting, a marked increase
in L-serine synthesis occurs in the liver (Kalhan and Hanson,
2012). In the central nervous system, L-serine is predominately
synthesized in astrocytes rather than neurons (Tabatabaie et al.,
2010).
From a structural and mechanistic point of view, the most
studied PGDH is that from E. coli (Pizer, 1963; Pizer and
Potochny, 1964; Rosenbloom et al., 1968; Sugimoto and Pizer,
1968a,b; Winicov and Pizer, 1974; Dubrow and Pizer, 1977a,b;
McKitrick and Pizer, 1980; Tobey and Grant, 1986; Schuller
et al., 1995; Al-Rabiee et al., 1996a,b; Grant et al., 1996, 1999a,b,
2000a,b, 2001a,b, 2002, 2003, 2004, 2005; Zhao and Winkler,
1996; Grant and Xu, 1998; Bell et al., 2002, 2004; Grant, 2004,
2011, 2012, 2018; Thompson et al., 2005; Dey et al., 2007; Burton
et al., 2008, 2009a), followed by that from M. tuberculosis (Grant
et al., 1999c; Dey et al., 2005a,b, 2008; Burton et al., 2007, 2009b;
Xu and Grant, 2014; Xu et al., 2015). There are also reports
from various animal tissues (Pizer, 1964; Walsh and Sallach,
1965; Cheung et al., 1969; Pizer and Sugimoto, 1971; Grant and
Bradshaw, 1978; Grant et al., 1978; Lund et al., 1986; Fell and
Snell, 1988; Achouri et al., 1997), other eukaryotes (Ulane and
Ogur, 1972; Ali et al., 2004; Singh et al., 2014), other bacteria
(Umbarger and Umbarger, 1962; Umbarger et al., 1963; Saski
and Pizer, 1975; Peters-Wendisch et al., 2002, 2005), and plants
(Hanford and Davies, 1958; Cheung et al., 1968; Slaughter and
Davies, 1968a,b; Rosenblum and Sallach, 1970). More recently,
investigations of PGDH from another bacterial species (Zhang
et al., 2017) and humans (Grant, 2012; Fan et al., 2015; Xu et al.,
2015; Unterlass et al., 2017) have been reported. PGDH has also
been implicated in abnormal neural development in humans
and as a potential cancer therapy target. These topics will be
referenced and discussed later in this review.

D -Serine is an agonist of the N -methyl- D -aspartate (NMDA)
receptor and it is synthesized from L-serine by serine racemase
(SR) (Fuchs et al., 2006; Ehmsen et al., 2013; Abe et al.,
2014). For nearly all organisms, including mammals, L-serine
is described as a non-essential amino acid because it is not
required in the diet, but is produced by a biosynthetic pathway
(Figure 1) (Sallach, 1956; Greenberg and Ichihara, 1957; Hanford
and Davies, 1958; Willis and Sallach, 1962, 1964; Walsh and
Sallach, 1966; Cheung et al., 1968; Nelson et al., 2009; Voet
and Voet, 2011). In these organisms, L-serine is made from
the glycolytic intermediate D-3-phosphoglycerate (PGA) and
the first enzyme in the L-serine biosynthetic pathway is D-3phosphoglycerate dehydrogenase (PGDH). It converts PGA to
phosphohydroxypyruvate (PHP) with the concomitant reduction
of NAD+ to NADH. To complete the pathway, phosphoserine
amino transferase (PSAT) converts PHP to L-phosphoserine (PS)
with the concomitant conversion of glutamate to α-ketoglutarate
(αKG), followed by the conversion of PS to L-serine with the loss
of phosphate by phosphoserine phosphatase (PSP). The official
designation of the genes coding for enzymes in this pathway differ
with species. For instance, in Escherichia coli, Mycobacterium
tuberculosis, and Homo sapiens, the gene coding for PGDH is
designated as serA1, Rv2996c, and PHGDH, respectively. In this
review, the designation “PGDH” will be used to refer to this
enzyme from any species.
The use of the term “non-essential” to describe L-serine is
unfortunate because it is a very important amino acid and is very
essential as the precursor to many metabolites. In addition to
being a precursor for D-Serine, L-serine is also a precursor for the
production of such metabolites as glycine, cysteine, tryptophan,
phosphatidyl L-serine, sphingolipids, purines, porphyrins,
glyoxalate, and glycine (Nelson et al., 2009; Voet and Voet,
2011). As the major precursor to glycine, it also contributes the
one-carbon unit (C1) that is the donor in methylation reactions
mediated by derivatives of tetrahydrofolate and S-adenosyl
methionine.
L -serine can also be produced from glycine by the action
of serine hydroxymethyl transferase (SHMT) (Nelson et al.,
2009; Voet and Voet, 2011). However, this is not a usual
or major route to the production of L-serine because it
depletes glycine levels as well as methylene tetrahydrofolate
which is the source of one-carbon units used for methylation
reactions. Many organisms, including mammals, also contain
a pathway that is often mistaken for a second pathway for
the production of L-serine. This so-called “un-phosphorylated”
pathway actually functions in L-serine degradation (Snell, 1986).
The enzyme that is a counterpart to PGDH in this pathway is
a D-glycerate dehydrogenase (GDH usually designated serA2)
and is located in the mitochondria in mammals (Snell, 1975)
and the peroxisomes in plants (Voet and Voet, 2011). The
existence of a catabolic pathway is necessary because the dephosphorylation of PS to produce L-serine is irreversible. The
“phosphorylated” pathway, located in the cytosol and utilizing
PGDH, is therefore the only anabolic source of L-serine in nonphotosynthetic organisms. In addition to being a precursor for
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PGDH TYPES
Although all PGDH enzymes (EC 1.1.1.95) catalyze the same
reaction, they exhibit certain mechanistic differences and they
can be divided into three structural types based on domain
structure (Grant, 2012) (Figure 2). Type 1 enzymes are composed
of four domains, the substrate binding domain, the nucleotide
binding domain, the ASB domain (where ASB stands for
allosteric substrate binding), and the regulatory domain which is
an ACT domain (Aravind and Koonin, 1999; Grant, 2006) (where
ACT stands for the first letters in Aspartate kinase, Chorismate
mutase, and TyrA). As will be discussed later, the regulatory
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FIGURE 1 | The L-serine biosynthetic pathway uses D-3 phosphoglycerate from glycolysis in the first step. D-serine is produced from L-serine by serine racemase.

FIGURE 2 | PGDH exists as three different types distinguished by domain structure. The domain structure, going from amino terminus to carboxyl terminus, is
illustrated for each type along with representative species containing each type. The “∼” symbol signifies that the enzyme from different species can contain different
lengths of amino acid sequence at the amino terminus.

domain designation is based on its role in the regulation of
enzyme activity by L-serine. Although it is often reported,
particularly in introductory textbooks, that PGDH in general
is feedback inhibited by L-serine (Walsh and Sallach, 1965;
Slaughter and Davies, 1968a; Rosenblum and Sallach, 1970; Fell
and Snell, 1988; Achouri et al., 1997), all mammalian enzymes
so far studied as well as those from many other species have lost
this ability. The ASB domain is so named because it functions as
a substrate binding regulatory site in PGDH from some species
(Dey et al., 2005a; Burton et al., 2007, 2009b). The function of the
other two domains corresponds to their designation, namely that
they function mainly in the binding of substrate and coenzyme.
Type 2 enzymes are missing the ASB domain and consist of a
substrate binding domain, a nucleotide binding domain, and a
regulatory (ACT) domain (Schuller et al., 1995). Type 3 enzymes
consist of only a substrate binding domain and a nucleotide

Frontiers in Molecular Biosciences | www.frontiersin.org

binding domain (Ali et al., 2004). In addition, as demonstrated
in Figures 2, 3, some, but not all, Type 3 enzymes utilize lysine as
the catalytic residue (Ali et al., 2004; Singh et al., 2014) instead of
the histidine that is found in all other PGDH types. Interestingly,
there does not appear to be a pattern of domain type associated
with type of organism. For instance, Type 1 enzymes containing
all four domains are found in mammals, plants, and bacteria and
Type 2 enzymes are found in eukaryotic organisms as well as
bacteria. It is important to note that the presence of a homologous
structural domain does not necessarily mean that it is functional.

PGDH HOMOLOGY
The amino acid sequence alignment of representative PGDHs is
shown in Figure 3. The numbering refers to position in the figure
rather than in any particular sequence. The types are shown

3
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FIGURE 3 | Amino acid sequence alignment of PGDH form representative species. Mt, Mycobacterium tuberculosis; Dr, Danio rerio (zebrafish); Rn, Rattus
norvegicus; Hs, Homo sapiens; Sc1 and Sc2, two variants from Saccharomyces cervisiae; Ec, Escherichia coli; Eh, Entamoeba hystolytica; Dm, Drosophila
melanogaster. The numbering designates residue position in the figure rather than the sequence of a particular PGDH. The PGDH type is shown as a numeral in front
of the species abbreviation. The domains are highlighted with colored lines. Substrate binding domain, blue; nucleotide binding domain, yellow; ASB domain, green;
and ACT domain, orange. Conserved residues are highlighted in yellow. Residues involved in L-serine binding at the ACT site are highlighted in green. The active site
lysine in some type 3 enzymes is highlighted in magenta. Asterisks designate residues involved in substrate and effector binding and the plus sign identifies the active
site histidine or lysine. The carboxyl termini are designated “Ct”.

The aromatic amino acid at position 187 forms the bottom of the
active site cleft. The glycine residues at positions 205, 207, and
210 and the aspartic acid residue at position 230 are conserved
residues in the Rossman fold involved in coenzyme binding.
The arginine residue at position 291 anchors the substrate into

before the species abbreviation and the domains are highlighted
with colored lines. Residues known to be involved in catalysis
or ligand binding are shown with an asterisk or a plus sign (see
Figure legend). The arginine residues at positions 106 and 189
are involved in interaction with the substrate phosphoryl group.

Frontiers in Molecular Biosciences | www.frontiersin.org
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inhibition by L-serine. However, in the presence of phosphate
ion, a conversion to active tetramers and active octamers
occurs. These two species are in equilibrium and both are very
sensitive to inhibition by L-serine. Small polyphosphates, such
as pyrophosphate and triphosphate, induce a conversion to an
active dimer that is insensitive to L-serine. A similar dependency
on phosphate ion for oligomeric state is also observed for human
PGDH (unpublished) which is also a Type I enzyme.
The dependency of activity on phosphate ion concentration
is further illustrated when the activity of M. tuberculosis PGDH
is monitored as a function of time (Dey et al., 2005b, Figure S2).
When the enzyme is diluted 500-fold in the presence of 200 mM
KPO4 buffer, the enzyme retains activity. However, a 500-fold
dilution in 20 mM KPO4 buffer results in a time dependent loss
of activity that fits best to a double exponential function. This
demonstrates that there are at least two enzyme forms that lose
activity with discernable dissociation constants. These forms
most likely correlate with the observed changes in oligomeric
state.
The mammalian enzymes are also Type I PGDHs. The subunit
molecular weight of human PGDH is 56,651, but it has been
crystallized only after removal of the ASB and ACT domains.
Therefore, it is not known if mammalian PGDHs adopt the same
internal asymmetry of the tetramer found in the M. tuberculosis
PGDH. Since they do not contain the triple glycine sequence
that presumably allows for the domain rotation found in M.
tuberculosis PGDH, it is possible that they do not share the
same tetrameric configuration. Furthermore, it is not known
whether M. tuberculosis PGDH actually adopts the asymmetric
conformation in solution. Since M. tuberculosis PGDH could
only be crystallized in the presence of 1 M tartrate, and a
tartrate molecule is found between adjacent ASB domains, it has
been speculated that the crystal structure may represent only
one of at least two alternative conformations and that these
alternative conformations may be responsible for the peculiar
phosphate dependent sensitivity to L-serine (see section Feedback
Inhibition) and the variations in oligomeric states.
A representative structure of a Type II PGDH is from E. coli
(Figure 5). It is a tetramer of identical subunits with respect to
amino acid composition and domain orientation with a subunit
molecular weight of 44,044. The tetramer is a dimer of dimers,
with one dimer interface at the nucleotide binding domains and
the other at the ACT or regulatory domains.
A representative structure of a Type III PGDH is from E.
histolytica (Figure 6). Since it lacks ASB and ACT domains, the
only subunit interface is at the catalytic domains resulting in a
dimeric configuration. Its subunit molecular weight is 33,469.

the active site by interaction with the substrate carboxyl group.
The active site histidine (or lysine) that donates a proton is at
position 353. The residues that participate in binding L-serine at
the regulatory site are at positions 537, 539, and 557.
A comparison of the conserved amino acid residues shows
that there is a relatively low degree of identity between human
PGDH and those of the non-mammalian PGDHs. There is
36.8, 31.9, and 24.5% identity of the nucleotide binding and
substrate binding domains combined, between Human and M.
tuberculosis, E. coli, and Entamoeba histolytica, respectively.
There is 30.7, 27.6, and 24.5% identity of all common domains
between Human and M. tuberculosis, E. coli, and E. histolytica,
respectively. There is only 8.4% identity of the ASB domains
between Human and M. tuberculosis, and 3.9 and 8.2% identity
of the ACT domains between Human and M. tuberculosis, E. coli,
respectively. Among mammalian species, such as between human
and rat PGDH, there is a 94.6% identity.

PGDH STRUCTURE
Oligomeric Conformations
The structure of PGDH differs depending on its domain makeup
or Type (Figures 4–6). The only complete PGDH structures
that have been determined and published are a Type I from M.
tuberculosis (Dey et al., 2005a, Figure 4), a Type II from E. coli
(Schuller et al., 1995, Figure 5), and a Type III from E. histolytica
(Singh et al., 2014, Figure 6). A partial structure of human
PGDH has been published (Unterlass et al., 2017) showing
the substrate and nucleotide binding domains but without the
ASB and ACT domains which were proteolytically removed
to facilitate crystallization. The structure of a Type II PGDH
from Brucella melitensis and Type III PGDHs from Lactobacillus
plantarum, Pyrococcus horokoshi, Sulfolobus tokodaii, Ralstonia
solanacearum, and Vibrio cholera have been deposited in the
RCSB protein data bank but have not been described in a
publication.
The one structure of a Type I PGDH that has been determined
is from M. tuberculosis (Figure 4). It is a tetramer with identical
subunits with a molecular weight of 54,522. However, the
subunits are identical with respect to amino acid composition
but not with respect to domain orientation (Dey et al., 2005a).
Interestingly, the subunits adopt two different conformations,
designated syn- and anti- (Figure 7), arranged in the tetramer as
shown in Figure 4 and which results in an internal asymmetry.
The syn- and anti-conformations differ by a rotation of ∼180◦
at a position composed of three consecutive glycine residues
(position 389–391 in Figure 3). This results in two different sets
of inter-subunit interactions between the nucleotide binding and
ASB domains resulting in different portions of the respective
subunits being exposed to solvent. A diagram of the subunit
domain orientations is provided in Figure 4 showing that the two
syn-conformers are in the middle and the two anti-conformers
are at the ends of the elongated tetramer.
M. tuberculosis PGDH has also been shown to exhibit multiple
oligomeric equilibrium states (Xu and Grant, 2014) modulated
by phosphate and polyphosphates (Figure S1). In the absence
of these ions, the enzyme is in equilibrium between an inactive
dimer and an active tetramer that is relatively insensitive to
Frontiers in Molecular Biosciences | www.frontiersin.org

Catalytic Sites
The basic mechanism of all PGDHs is the same. The substrate,
PGA, is oxidized by the transfer of a proton to the active site
histidine or lysine and a hydride ion to NAD+ , to yield PHP.
The catalytic site of human PGDH with NAD and malate bound
is depicted in Figure 8. The three cationic residues that interact
with the acidic ends of the substrate are shown and are common
to all PGDH active sites. In Figure 3, Arg 53 corresponds to
position 107, Arg 134′ to position 189, Arg 235 to position 291,
and His 282, which is the proton donor, to position 353. Arg
5
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FIGURE 4 | Crystal structure of a Type I PGDH from M. tuberculosis. On the left, each subunit is colored differently. In the center is a diagram of the subunits showing
the course of the polypeptide chain from amino terminus, designated by a black dot, to the carboxyl terminus. On the right, the individual domains are colored
according to the scheme shown below the structure. Representative species with Type 1 enzymes are listed.

significant domain and loop movements are likely related to
coenzyme binding in solution. Superimposing the human and
M. tuberculosis PGDH catalytic sites shows that the latter has a
more open cleft, requiring a rotation for closure, but the PHP is
in approximately the same position as the malate in the human
structure. In E. coli PGDH, Arg 60 corresponds to position 107,
Lys 141′ to position 189, Arg 240 to position 291, and His 292 to
position 353. Note that in E. coli PGDH a lysine residue is present
at position 189 instead of an arginine. NAD is not present in the
M. tuberculosis structure because it binds after a conformational
change induced by substrate binding. For both E. coli and M.
tuberculosis PGDH, a rotation of the substrate binding domain
relative to the nucleotide binding domain is necessary to close
the cleft and move the various elements into place for catalysis.

235 interacts with the carboxyl of PGA/PHP while the other
two arginine residues interact with the phosphate group. In this
depiction, the active site is closed, but since malate is a shortened
version of the substrate, the spatial configuration of the residues
is not optimal. The active sites in the crystal structures of E.
coli and M. tuberculosis PGDH (Figure 8) are in a more open
configuration, as if they are poised just prior to closing of the
active site cleft. The open conformation of the active site may
be due to crystal packing constraints that aren’t in play with the
human structure since the ASB and ACT domains are missing in
the crystallized form reported. In M. tuberculosis PGDH, Arg 51
corresponds to position 107, Arg 132′ to position 189, Arg 233 to
position 291, and His 280 to position 353.
The order of substrate and coenzyme binding in E. coli
PGDH (Grant et al., 2002) and Pseudomonas species PGDH
(Zhang et al., 2017) is coenzyme before substrate. This is also
apparently the case for human PGDH (Unterlass et al., 2017)
since the crystal structure contains NADH (Unterlass et al.,
2017). However, this has not been determined conclusively
from kinetic analysis of the complete enzyme. The order in M.
tuberculosis PGDH is substrate before coenzyme, opposite of that
for the others. The crystal structures of M. tuberculosis PGDH
show that the coenzyme sites have restricted access to solvent.
In the syn-conformation, the coenzyme site is covered by the
ASB domain, resulting in a narrow channel leading to solvent.
In the anti-conformation, the ASB is rotated away from the
coenzyme site but is blocked by a long flexible loop. Therefore,

Frontiers in Molecular Biosciences | www.frontiersin.org

Effector Binding at the ACT and ASB
Domain Interfaces
In the Type II PGDH from E. coli, feedback inhibition of catalytic
activity occurs when L-serine binds at the ACT domain interface
as shown in Figure 9. The serine carboxyl group hydrogen
bonds to the imidazole nitrogen of His 344 (position 537 in
Figure 3), and the amino group of serine bonds to the amide
side chains of Asn 346 (position 539) and Asn 364′ (position
557). The hydroxyl group of serine does not form hydrogen
bonds directly with an amino acid but rather interacts through
a water molecule with the main chain carbonyl groups of Thr

6

December 2018 | Volume 5 | Article 110

Grant

D-3-Phosphoglycerate Dehydrogenase

FIGURE 5 | Crystal structure of a Type II PGDH from E. coli. On the left, each subunit is colored differently. In the center is a diagram of the subunits showing the
course of the polypeptide chain from amino terminus, designated by a black dot, to the carboxyl terminus. On the right, the individual domains are colored according
to the scheme shown below the structure. Representative species with Type II enzymes are listed.

352 (position 545) and Val 363′ (position 556). When serine
binds, there is a rotation of the substrate binding domain-ACT
domain relative to the nucleotide binding domain. This has a
significant effect on the conformation of the active site and is
likely responsible for the inhibition of activity caused by serine
binding. L-serine enters the effector site through an opening
at the surface around Asn 364′ . Upon binding, the opening
is covered by movement of Asn 364′ and Pro 348 (Figure 9).
The two binding sites at each ACT domain interface assume
different conformations in the absence of serine. One is open
and one is closed similar to the structure seen when serine is
bound. Since all four sites are occupied in the crystal structure
(pdb 1psd), the binding of L-serine to the open site apparently
induces the other site to open. Binding studies (Grant et al.,
2001b) show that serine binding is positively cooperative for the
first two sites in the tetramer, located at opposite ACT domain
interfaces, and negatively cooperative for the last two sites to be
occupied.
In M. tuberculosis PGDH, L-serine is bound at the interface of
the ACT domains (Figure 9) as it is in E. coli PGDH. However,
the interaction with serine is somewhat different. The serine
carboxyl group is hydrogen bonded to the hydroxyl group of Tyr
461 (position 537 in Figure 3) and the side chain oxygen of Asp
463 (position 539). The amino group of serine hydrogen bonds
to the side chain of Asn 481′ on the opposite subunit (position

Frontiers in Molecular Biosciences | www.frontiersin.org

557) and the serine hydroxyl is hydrogen bonded directly to main
chain amide of Leu 468 (position 544). As is the case with E. coli,
the pocket closes when serine binds as a result of Asn 481′ moving
over the pocket opening. This is accompanied by a movement
of Asp 463 and Arg 464 (positions 539 and 540) with Asp 463
forming an additional hydrogen bond with serine.
The crystal structure of M. tuberculosis PGDH contains a
molecule of tartrate bound at the interface of adjacent ASB
domains (Figure 10). This site is populated with a number of
cationic residues that interact with the tartrate, including Lys
439, Arg 446, His 447, Arg 451, and Arg 501 (positions 512,
519, 520, 524, and 576, respectively, in Figure 3). Note that Arg
501 is actually in the ACT domain and produces the largest
decrease in serine inhibition when it is mutated to alanine
(Burton et al., 2009b). Since tartrate is an analog of the substrate,
it was originally proposed that this may be an allosteric substrate
binding site. Alteration of the residues at the ASB interface
by mutagenesis, demonstrated that this site appeared to bind
substrate which resulted in an attenuation of catalytic activity
(Burton et al., 2009b; Grant, 2012). It has also been proposed,
but not definitively shown, that this is also the phosphate binding
site and that interplay between substrate and phosphate ion at
this site results in phosphate dependent inhibition of catalytic
activity when serine binds to the ACT domain (Xu and Grant,
2014).

7
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FIGURE 6 | Crystal structure of a Type III PGDH from E. hystolytica. On the left, each subunit is colored differently. In the center is a diagram of the subunits showing
the course of the polypeptide chain from amino terminus, designated by a black dot, to the carboxyl terminus. On the right, the individual domains are colored
according to the scheme shown below the structure. Representative species with Type III enzymes are listed.

FIGURE 7 | The syn- (right) and anti- (left) configurations of the subunits of M. tuberculosis PGDH. The subunits are pictured with their substrate (blue) and
nucleotide (yellow) binding domains in essentially the same orientation. The ASB (green) and ACT (orange) domains are rotated to the left in the anti-configuration and
to the right in the syn-configuration.

REGULATION OF CATALYTIC ACTIVITY

the equilibrium of the reaction, substrate inhibition, and
feedback inhibition. However, as noted previously, all
three are not necessarily operative in PGDH from all
organisms.

The production of L-serine is regulated at the level of
enzyme activity of PGDH by three main mechanisms:

Frontiers in Molecular Biosciences | www.frontiersin.org
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FIGURE 8 | (Top) Depiction of the active site of human PGDH from pdb 2g76 with malate and NAD bound. Some of the alpha chain in the background has been cut
away for clarity. (Bottom) Depiction of the active site of E. coli PGDH from pdb 1yba (left) and of M. tuberculosis PGDH from pdb 2ddn (right).

FIGURE 9 | (Left) The ACT domain interface in E. coli PGDH showing the interaction of L-serine with specific residues. Reprinted from Grant (2012). (Top Right) The
serine binding site in E. coli PGDH. The serine atoms are shown as spheres in the right-hand structure. Reprinted from Grant (2012), with permission from Elsevier ©
2011. (Bottom Left) The serine binding site in M. tuberculosis PGDH. The serine atoms are shown as spheres in the left-hand structure. Reprinted from Grant (2012),
with permission from Elsevier © 2011.

Frontiers in Molecular Biosciences | www.frontiersin.org
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FIGURE 10 | The relationship of the ACT (orange) and ASB (green) domains in M. tuberculosis PGDH. The depiction on the left shows the domains in the absence of
bound ligands and the depiction on the right shows L-serine and tartrate bound at their respective sites. The stick model at the bottom shows the specific residue
interactions seen in the crystal structure.

Catalytic Activity and the Equilibrium State
of the Reaction

not the case for M. tuberculosis and human PGDH, where the
production of NADH can be measured in the coupled reaction.
The kinetic constants for PGDH from several species are listed in
Table 1.

The equilibrium of the reaction catalyzed by PGDH lies far
in the direction of PGA, opposite of that leading to serine
synthesis (Sugimoto and Pizer, 1968b). At equilibrium, <5% of
the substrates and products are in the form of PHP. The reaction
is pulled in the forward direction by the downstream enzymes
despite the strong tendency for PGDH to act in the opposite
direction. The reaction catalyzed by PSAT is freely reversible,
but the de-phosphorylation of L-serine by PSP is not reversible
and is the point of no return. This latter reaction, in effect, acts
like a sink, keeping serine from being depleted by reaction in
the reverse direction and assuring that the flux of the pathway
continues in the direction of L-serine synthesis.
As a result of the equilibrium state of the reaction, it is
difficult to assay PGDH in the forward direction and historically
it has been assayed mostly in the reverse direction using PHP
as the substrate. Forward assays using PGA as the substrate
usually employ fluorescence monitoring for sensitivity and
with hydrazine added, presumably to trap the PHP produced
(Sugimoto and Pizer, 1968b), but they are difficult to perform
accurately. In order to measure the activity of PGDH in the
forward direction, it is best to use a coupled assay that depletes
either PHP or NAD+ in order to drive the reaction forward.
However, as noted below (see section Alternate Substrates), the
activity of E. coli PGDH cannot be measured by monitoring the
formation of NADH when coupled with PSAT because of its
conversion back to NAD+ by αKG generated by PSAT. This is
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Substrate Inhibition
In addition to the equilibrium of the PGDH catalyzed reaction
favoring PGA, human and M. tuberculosis PGDH exhibits
significant substrate inhibition by PHP (Xu et al., 2015,
Figure S3). Therefore, theoretically, if PHP were to accumulate
to a certain level, its conversion to PGA would be inhibited,
counteracting to some extent the equilibrium tendency of the
reaction. However, there are no definitive studies of pathway flux
that demonstrate that this is functional physiologically. PHP is
inherently unstable and the investigations of metabolite levels
that are available (in bacteria, Bennett et al., 2009) don’t list PHP
as a measurable metabolite. Substrate inhibition by PHP is also
less pronounced in phosphate buffer than other buffers that have
been reported (Xu et al., 2015).

Feedback Inhibition
As noted earlier, textbooks often refer to PGDH as being
inhibited by the end-product of the pathway, L-serine. While
this is true for PGDH from some organisms, it does not pertain
to that from all species. When it does occur, it results from
the interaction of L-serine with the regulatory or ACT domain.
However, the sensitivity of PGDH to L-serine concentration
varies greatly. PGDH from Bacillus subtilis (Saski and Pizer,
1975) and Corynebacterium glutamicum (Peters-Wendisch et al.,
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TABLE 1 | Catalytic properties of D-3-phosphoglycerate dehydrogenasea .
Reaction

Km, substrate (mM)

Km,coenzyme (mM)

kcat (s−1 )

kcat /Km, substrate (M−1 s−1 )

L-Serine IC50 (Hill coefficient)

(µM)
E. coli
PHP reductione

0.0032b

<0.01

28b

∼9 × 106b

2–13d (∼2)

αKG reductione

0.088b

<0.01

12–33d

∼4 × 105b

2–8d

PGA oxidation

1.2b

NDc

0.6b

∼5 × 102b

44

HGA oxidation

0.4b

NDc

0.7b

∼2 × 103b

36

PGA oxidationh (PGDH/PSAT)

NDSc
0.06f

2,400

∼1 × 107

36(∼2)

M. tuberculosis
PHP reductione

0.17

αKG reduction

DNRc

PGA oxidation

NDc

HGA oxidation

NDc

PGA oxidation MOPSh
(PGDH/PSAT) POf,h
4

0.54

0.06

1.4

2.6 × 103

9.2

5.2

3

3.3 × 102

13 (1.5)

0.10

0.02

300

∼3 × 103

DNIc

0.49

0.4

0.8 × 103

DNIc

HUMAN
PHP reductione
KG reduction
PGA oxidationh MOPS (PGDH/PSAT)

DNRc
0.48

RATe
PHP reductione

∼0.015g

0.025

NDc

NDc

DNIc

PGA oxidation

0.1

0.027

NDc

NDc

DNIc

αKG reduction

DNRc

a

PHP, phosphohydroxypyruvic acid; αKG, α-ketoglutarate; PGA, D-3-phosphoglycerate; HGA, D-hydroxyglutaric acid. Values are per tetramer.
From Zhao and Winkler [29].
ND, not determined; DNI, does not inhibit; DNR, does not react; NDS, not detectable spectrophotometrically at 340 nm.
d Value varies slightly from different groups. Note that in all cases, all of the kinetic parameters can vary depending on the buffer used.
e Exhibits substantial substrate inhibition in phosphate buffer, pH 7.0.
f Unpublished.
g Estimated from Achouri et al. (1997).
h From Grant (2018).

b
c

et al., 2000a, 2005). Since Type III PGDH enzymes do not
contain an ACT domain, they are not feedback regulated by
L -serine.
E. coli PGDH contains a Gly–Gly sequence (Gly 336–Gly
337 corresponding to positions 397–398 in Figure 3) between
the substrate binding domain and the regulatory domain that
acts like a hinge and plays a role in the conformational change
that takes place upon serine binding and that is responsible
for inhibition of activity (Grant, 2011). A similar sequence is
found in M. tuberculosis PGDH (Gly 316–Gly 317–Gly 318,
corresponding to positions 389–391 in Figure 3) but not in
human PGDH. The absence of this hinge region in human PGDH
is a contributing factor to its lack of feedback regulation by
L -serine.

2002, 2005) are Type I enzymes that are relatively insensitive
to L-serine, with IC50 -values of ∼5 and 10 mM, respectively.
On the other hand, the Type I PGDH from M. tuberculosis has
an IC50 for L-serine of ∼30 µM, but only in the presence of
phosphate ion (50–100 mM). In the absence of phosphate, the
IC50 is in the low mM range (Xu and Grant, 2014) similar to
that for B. subtilis and C. glutamicum. The available evidence
shows that L-serine will bind to the ACT domain in the absence
of phosphate ion but it is the interaction of phosphate at the ASB
domain that allows L-serine to inhibit activity in the micromolar
range (Burton et al., 2009b; Xu and Grant, 2014). However,
the phosphate dependent sensitivity to L-serine does not occur
with all mycobacteria (Xu et al., 2015) although it seems to be
consistent among pathogenic mycobacteria to the extent that it
has been studied. PGDH from all mammalian sources that have
been studied show no sensitivity to serine at all, even though
they contain ACT domains (Achouri et al., 1997; Dey et al.,
2008; Grant, 2012). In these cases, the ACT domain residues
are altered so that they no longer bind serine (see Figure 3).
The classical feedback regulation by L-serine occurs with the
Type II PGDH from E. coli which has an IC50 for L-serine of
2–10 µM, depending on the buffer used in the assay (Grant
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ALTERNATE SUBSTRATES
In 1996, Zhao and Winkler discovered that E. coli PGDH could
use α-KG as a substrate in the reverse direction in place of PHP
(Zhao and Winkler, 1996) to produce α-hydroxyglutarate (αHG) with the concomitant oxidation of NADH. The ability to
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use αKG as a substrate has also been reported for Pseudomonas
stutzeri (psPGDH) (Zhang et al., 2017), Pseudomonas aeruginosa
(paPGDH) (Zhang et al., 2017), Saccharomyces cerevisiae
(scPGDH) (Becker-Kettern et al., 2016), and human PGDH
(hsPGDH) (Fan et al., 2015). However, the level of activity of
human PGDH for α-KG is relatively low with a kcat of ∼0.08 s−1
compared to that for E. coli PGDH of 33 s−1 (Fan et al., 2015).
PGDH from Mycobacterium tuberculosis (mtPGDH) (Dey et al.,
2005b) and Rattus norvegicus (Achouri et al., 1997) are reported
to not use α-KG as a substrate. Zhang et al. (Zhang et al., 2017)
have shown in Pseudomonas species, that the coupling of this
reaction with d-2-hydroxyglutarate dehydrogenase can serve to
drive L-serine synthesis. Grant (2018) has shown that in E. coli,
there is a process that conserves coenzyme in the production
of L-serine by utilizing an intrinsic cycle of NAD+ /NADH
interconversion coupled with the conversion of αKG to αHG.
Interestingly, this cycle can be maintained in vitro by production
of αKG by the second enzyme in the pathway, PSAT, and does
not require any additional enzymes (Figure 11). However, there
is probably an ample pool of αKG available in vivo so that this
is not strictly required. Note also that the kinetic mechanism
shown in Figure S4 is for the reverse direction where NADH can
displace NAD+ . Therefore, the NADH conversion cycle is likely
not functional in this direction.
No other compounds have been found to display significant
activity as substrates. However, several NAD analogs have been
demonstrated to be able to substitute for the coenzyme (Walsh
and Sallach, 1965; Sugimoto and Pizer, 1968b; Rosenblum
and Sallach, 1970; Winicov and Pizer, 1974; Unterlass et al.,
2017). These include thionicotinamide adenine dinucleotide
in wheat germ and human PGDH, 3-acetylpyridine adenine
dinucleotide in wheat germ, E. coli, chicken liver, and human
PGDH, 3-acetylpyridine deamino adenine dinucleotide in wheat
germ and chicken liver PGDH, deamino nicotinamide adenine
dinucleotide in E. coli and chicken liver PGDH, and 3pyridinealdehyde adenine dinucleotide in chicken liver and
human PGDH. Note, however, that not all coenzyme analogs

have necessarily been tested with each species. In all cases,
NADP+ displays <10% of the activity of NAD+ .

MECHANISM
Only E. coli (Grant et al., 2003, 2004; Burton et al., 2008, 2009a;
Grant, 2018) and M. tuberculosis (Grant et al., 1999c; Dey et al.,
2005a,b, 2008; Burton et al., 2007, 2009b; Xu and Grant, 2014; Xu
et al., 2015) PGDHs have been studied extensively with regard
to mechanism. A previous review (Grant, 2012) summarized the
findings of these studies in detail so they will only be briefly
summarized here.

E. Coli PGDH
The mechanism of E. coli PGDH was studied in the reverse
direction using α-KG and exhibits an ordered Bi Bi mechanism
where NADH must be present before substrate binds (Burton
et al., 2008). The kcat of E. coli PGDH in the reverse direction
is relatively slow at 7 s−1 per subunit with PHP as substrate.
In the forward direction, the kcat is ∼0.6 s−1 in an uncoupled
reaction with PGA as substrate. It has not been measured in
the forward direction by coupling it to PSAT and monitoring
the reduction of NAD+ because of the rapid regeneration of
NAD+ from NADH described above (Figure 11). E. coli PGDH
is isolated with tightly bound NADH and, for a long time, it
was thought that only NADH was tightly bound to the resting
enzyme. However, recent evidence (Grant, 2018) has shown that
NAD+ is also rather tightly bound to the enzyme although
it can be displaced by NADH. Both coenzyme forms appear
to remain bound to the enzyme during continuous turnover
when coupled to PSAT and participate in a cycle where they are
continuously regenerated in situ (Grant, 2018). The sites that lie
across the nucleotide binding domain interface appear to operate
in a “flip-flop” manner (Figure S5), with each site trading places
functionally after each turnover (Grant et al., 2003, 2004; Grant,
2018).
When enzyme catalysis is studied in the reverse direction
with enzyme in which all of the NADH has been converted
to NAD+ , there are two kinetically distinguishable NADH
binding phenomena (Burton et al., 2008, Figure S4). One where
coenzyme is very tightly bound and induces a conformational
change that increases the dissociation constant for coenzyme
even more, and one that is less tightly bound (Burton et al., 2008).
The former, found in the resting enzyme, can turn over in the
presence of substrate but the latter is the one that is functional
during continuous turnover. That is, the conformational change
that occurs with the binding of NADH in the absence of substrate
does not occur to an appreciable extent during continuous
turnover. Note that these “sites” are distinguished kinetically
rather than positionally. Also note that this was determined for
E. coli PGDH and is likely not the same for human and M.
tuberculosis PGDH.
A type of half-of-the-sites activity appears to be functional
for inhibition of activity by serine binding (Grant et al., 2004).
Although all four effector sites in the ACT domains eventually
bind serine, only two, on opposite sides of the nucleotide binding
domain, need to be occupied for optimal inhibition. Binding to

FIGURE 11 | The self-sustaining cycle that regenerates coenzyme bound to
PGDH during biosynthesis of L-serine in E. coli. The NADH that is produced
during the conversion of PGA to PHP is converted back to NAD+ in situ by
conversion of αKG to αHG. The αKG is formed from glutamate by the second
enzyme in the pathway, PSAT. Reprinted from Grant (2018) with permission
from the American Chemical Society.
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It is not known what the exact nature of the interaction of NADH
with the ASB site is, but it does not have an inhibitory effect on the
rate of catalysis. The dissociation constants for substrate binding
to the catalytic and ASB sites are 0.09 and 8 µM, respectively.
Other than L-serine, which effectively inhibits M. tuberculosis
PGDH only in the presence of substantial concentrations of
phosphate ion, no other inhibitors, natural or synthetic, have
been identified for PGDH from mycobacteria. However, our
unpublished work has demonstrated that CBR5884, a potent
inhibitor of human PGDH (Mullarky et al., 2016), does not
inhibit M. tuberculosis PGDH. This limited evidence suggests
that specific inhibitors could be found for PGDH from different
species, and therefore, in light of the essential metabolic role
of L-serine in metabolism, this is an area in need of further
exploration.

these two sites displays positive cooperativity. Binding of serine
to the last two sites is weaker due to negative cooperativity across
the ACT domain interfaces.
The catalytic activity of E. coli PGDH can be inhibited
in a reversible manner by cross-linking adjacent regulatory
(ACT) domains with a disulfide bridge (Al-Rabiee et al., 1996a).
Furthermore, this inhibition can be completely reversed by
reduction of the bridge with dithiothreitol. This suggests that the
regulatory domains move in some manner relative to each other
during the transition from active to inhibited state. The disulfide
bridge appears to mimic the binding of inhibitor since L-serine
binds across the regulatory domain interface linking the two
domains. Therefore, the mechanism of inhibition is one where
serine binding eliminates a conformational change resulting from
substrate binding and forms a dead-end quaternary complex
consisting of enzyme, coenzyme, substrate, and effector (Burton
et al., 2009a). Thus, the mechanism is a V-type that results in the
reduction of active species rather than in a graded modulation of
the velocity of the active enzyme.
Tryptophan 139 (position 187 in Figure 3), which sits at the
bottom of the catalytic site of the adjacent subunit, plays a critical
role in the oligomeric state of the enzyme as well as the integrity
of the catalytic site (Grant et al., 2000b). When it is converted
to a glycine residue, the enzyme dissociates into dimers and is
600-fold less active. However, it is just as sensitive to inhibition
by L-serine as the native enzyme, although the cooperativity of
inhibition is lost. It is quite surprising that a single residue can
have such a drastic effect on the oligomerization state given that
there is extensive subunit-subunit contact in this region, but this
result demonstrates its critical importance. That this tryptophan
is conserved in all other tetrameric PGDHs, suggests it plays a
similar role in their catalytic and structural integrity.
Other than L-serine, which is a very potent inhibitor of E.
coli PGDH, no other natural inhibitors have been identified.
However, several heterocyclic organic inhibitors have been
reported from studies involving predicted allosteric sites (Qi
et al., 2012; Wang et al., 2014).

Human PGDH
No detailed studies of the mechanism of human PGDH have
been reported but the kinetic constants for human PGDH are
similar to those for M. tuberculosis PGDH when coupled to PSAT,
with the exception that the K m for NAD+ is ∼8-fold higher
for the human enzyme. Like E. coli PGDH, the enzyme appears
to contain bound cofactor when isolated and the binding order
appears to be coenzyme before substrate (Unterlass et al., 2017).
Although the human enzyme has been reported to slowly convert
αKG to αHG (Fan et al., 2015), the measured rate of conversion
is very slow (Fan et al., 2015) and it does not sustain a coenzyme
conservation cycle like that reported for E. coli PGDH (Grant,
2018). As mentioned earlier, while human PGDH is a Type 1
enzyme, it is not regulated by L-serine. In fact, human PGDH,
as well as other mammalian PGDHs, have not been found to
be regulated by any small molecule. Therefore, any regulation of
human PGDH occurs either at transcription or translation or in
the case of genetic mutations of amino acid residues as described
below.

CONGENITAL DEFECTS ASSOCIATED
WITH THE LACK OF PGDH IN MAMMALS

M. tuberculosis PGDH
The kcat of 600 s−1 per subunit in the reverse direction for M.
tuberculosis PGDH is much faster than that of E. coli PGDH.
However, when coupled to PSAT in the forward direction, it is
only 1.4 and 3 s−1 at pH 7.0 in MOPS and phosphate buffer,
respectively. The kinetic mechanism is also ordered Bi Bi, but in
this case, substrate binds before coenzyme. Although the order
was determined with a reverse direction assay, it is consistent
with the observation that the E. coli enzyme crystallizes with
coenzyme and shows strong affinity for 5′ -AMP Sepharose, an
NAD analog, while the M. tuberculosis enzyme does not crystalize
with coenzyme bound to the active site and has no affinity for 5′ AMP Sepharose. Interestingly, pre-steady state analysis showed
that NADH could in fact bind to the enzyme in the absence of
substrate but that the binding constants were too slow to account
for the catalytic reaction (Dey et al., 2008, Figure S6). Subsequent
investigation (Burton et al., 2009b; Grant, 2012) indicated that
NADH bound at or near the ASB site and reduced the amount of
substrate inhibition due to substrate interaction at the ASB site.
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Serine deficiency disorders, which are caused by defects in the
pathway leading to the synthesis of L-serine, were first reported
in 1996 (Jaeken et al., 1996) and are mostly neurological in nature
(Yoshida et al., 2004; Furuya, 2008; van der Crabben et al., 2013;
El-Hattab et al., 2016). Although defects in the expression or
catalytic activity of any of the three biosynthetic enzymes in the
pathway can lead to L-serine deficiency (Tabatabaie et al., 2010;
van der Crabben et al., 2013), those related to PGDH deficiency
are the most common. The important role of PGDH was shown
with a knock-out mouse model. The phenotype was associated
with embryonic lethality and clearly demonstrated the L-serine
biosynthetic pathway was critical (Yoshida et al., 2004).
That L-serine synthesized in the brain was the source of Dserine in the mature brain was shown using a conditional knockout of PGDH in the brain that bypassed the embryonic lethal
phenotype resulting from systemic deletion (Yang et al., 2010).
The study found that both L-serine and D-serine levels were
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significantly decreased in the cerebral cortex and hippocampus
without altering levels of SR and NMDA receptor subunits.
The study concluded that “in mature neuronal circuits, L-serine
availability determines the rate of D-serine synthesis in the
forebrain and controls NMDA receptor function at least in the
hippocampus.”
Infantile, juvenile, and adult onset phenotypes have all been
reported for PGDH deficiency (Tabatabaie et al., 2010; van der
Crabben et al., 2013). In the infantile phenotype, damage to the
brain has already occurred prior to birth and usually manifests
itself with congenital microcephaly, intractable seizures, and
severe psychomotor defects. In general, oral supplementation
with L-serine is very effective in reducing seizures but has
little effect on psychomotor function. The juvenile phenotype
was found in two siblings and traced to a single amino acid
mutation. These patients first showed symptoms after 5 and
9 years of age and were not diagnosed as such until they
were teenagers. The symptoms were much milder than in the
infantile phenotype, consisting of absence seizures and moderate
developmental delay without microcephaly. Both responded well
to oral supplementation with L-serine. The adult phenotype
in a single individual consisted of congenital cataracts, mental
retardation in childhood, and progressive polyneuropathy as an
adult.
One mutation, in particular, has been found as a common
cause of PGDH deficiency, having been found in at least seven
different individuals (Tabatabaie et al., 2010). This mutation,
Val490Met, is found in the regulatory or ACT domain of PGDH.
It is not known how it results in PGDH deficiency and the
literature contains conflicting conclusions. One group (Pind
et al., 2002) reports that the mutation results in a decrease
in expression and an increase in degradation of PGDH, while
another group (Tabatabaie et al., 2009) concluded that the
mutation was without effect on expression and degradation,
but rather produced an enzyme with low residual activity. It
is interesting to note that the mutation is in the ACT domain
and if the human structure is the same as that reported for
PGDH from M. tuberculosis, the side chain of residue 490
would be found at the subunit interface between the ASB/ACT
domains from adjacent subunits. Although far from the catalytic
site, this mutation could result in an interference of structural
integrity of the oligomer that could result in reduced activity and
enhanced susceptibility of enzyme to degradation, which could
be consistent with both literature reports.

cancer has occurred within the last 10 years or so with the
observation that an increased level of expression of PGDH has
been found in human cancers such as breast (Possemato et al.,
2011), cervical (Zhang et al., 2015), glioma (Liu et al., 2013),
melanoma (Ou et al., 2015), colon (Yoon et al., 2015), pancreatic
(Zhiwang et al., 2018), liver (Shanshan et al., 2017), kidney
(Yoshino et al., 2017), and others as well. Based on multiple
lines of evidence (Mattaini et al., 2016), the phosphorylated
pathway of serine biosynthesis, which utilizes PGDH, is the
sole source of serine synthesis in non-photosynthetic organisms,
including humans. In most cases, tumor cell proliferation is
associated with increased levels of PGDH and decreased cell
proliferation is seen when PGDH is knocked out, even though
exogenous L-serine is supplied. In addition, inactive PGDH, due
to site-specific mutation, cannot support proliferation of PGDHdependent cells (Mattaini et al., 2015). It has also been shown
that increased levels of PGDH synthesis, as well as the other
serine biosynthetic enzymes, correlates with patient survival
outcome and may be used as a prognostic factor for some cancers
(Antonov et al., 2014). In some cases, extracellular serine seems
sufficient to promote tumor cell proliferation, whereas in other
cases, extracellular serine is not able to support cell proliferation
when PGDH is absent. For instance, adding excess serine to the
growth medium of PGDH knockdown human breast cancer cells
was not able to rescue cell proliferation (Possemato et al., 2011;
Chen et al., 2013). This suggests that flux through the serine
biosynthetic pathway is providing something other than just a
source of serine. In those cases where extracellular serine seems
sufficient, additional reactions may promote flux through the
pathway (Figure S7). It is still unknown just what the link is, but
the requirement for pathway flux suggests that increased levels of
the pathway intermediates, such as PHP or phosphoserine, may
be critical. This has become a very active area of investigation in
recent years and more detailed information on the link between
cancer and PGDH can be found in several reviews (Luo, 2011;
Mullarky et al., 2011; Zogg, 2014; Mattaini et al., 2016).
As a result of the correlation between high PGDH expression
levels and cancer, there has been interest in finding inhibitors
of the enzyme activity as potential starting points for drug
development. Several recent articles have reported advancements
in this area (Mullarky et al., 2016; Pacold et al., 2016; Wang et al.,
2016; Ravez et al., 2017; Unterlass et al., 2018).

SUMMARY AND PROSPECTIVE
PGDH AND CANCER

D -3-Phosphoglycerate dehydrogenase catalyzes the same
reaction in all known organisms where it is found. That
is, the NAD+ /NADH dependent interconversion of Dphosphoglycerate and PHP. However, there are significant
differences among organisms as to how or whether PGDH
activity is regulated by other factors. In all organisms where it
has been studied, the equilibrium of the PGDH reaction lies
far in the direction away from serine synthesis. Therefore, the
downstream enzymes play a large role in keeping the pathway
flux moving in the direction of serine synthesis by depleting
PHP and then phosphoserine. The last reaction of the pathway is

In 1970, Davis et al. (1970) published the first indication that
changes in serine biosynthesis may be related to cancer. This
work showed that PGDH activity was greater in rat hepatoma cell
lines compared to normal liver cells, and correlated the fastest
growth rate with the highest PGDH activity. Subsequent work
(Snell, 1984) showed that this was true in many other tumors as
well, and that among the pathway enzymes, tumor growth was
most consistently correlated with an increase in PGDH activity.
Renewed interest in the link between serine biosynthesis and
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relative to the M. tuberculosis enzyme, another Type I PGDH.
The availability of a complete structure of human PGDH will also
be necessary in the evaluation and fine tuning of inhibitors that
may eventually be developed into drugs targeting PGDH activity
in malignant cells and tumors.
From a physiological viewpoint, a thorough analysis of the
flux of the serine biosynthetic pathway in mammalian astrocytes,
in response to different stimuli, will be useful. An even broader
question in this respect concerns the interplay between glycolysis,
gluconeogenesis, and serine synthesis. If the L-serine biosynthetic
pathway in mammals lacks any type of specific regulatory
mechanisms to control the production of L-serine, what factors
govern consumption of the common metabolite, PGA? Asked
another way, what keeps the serine pathway in these organisms
from consuming an excess of PGA and adversely affecting energy
production from glucose?
The studies conducted with malignant mammalian cells
demonstrate that the expression of PGDH can be modulated, but
the precise factors leading to changes in expression levels are not
well-understood. This would also seem to be an area requiring
further investigation that may be relevant not only to cancer but
to neurological function as well.

irreversible, so once L-serine is produced it cannot be converted
back to PS by simple reversal of the pathway. This presumably
provides a relatively stable pool of L-serine that is available for
conversion into other metabolites like D-serine. In E. coli, for
example, there exists a very sensitive regulation of PGDH activity
by L-serine that provides for fine tuning of the L-serine pool.
A similar feedback mechanism exists in M. tuberculosis PGDH,
except that the enzyme’s sensitivity to L-serine is modulated by
the available phosphate ion content. Yet, in other organisms,
such as C. glutamicum and some plants, the serine sensitivity is
as much as three orders of magnitude less. In humans, inhibition
of PGDH by L-serine does not occur.
Very little is known about the regulation of PGDH or
the serine biosynthetic pathway itself in mammalian cells or
organisms, including H. sapiens especially. The attraction to the
bacterial enzymes for detailed investigation may be partly due to
the perception that the bacterial enzymes are more interesting
from an enzymological point of view in that the human enzyme
does not appear to be regulated by an effector molecule such
as L-serine. This lack of feedback control in human PGDH
may provide for a relatively large pool of available serine for
conversion into other metabolites as well as protein synthesis.
Although the literature is very sparse in this regard, it does not
seem that the other enzymes in the serine biosynthetic pathway
in mammals display any significant level of regulation by small
molecule effectors. Since the available literature clearly points to
the availability of L-serine as being critical to the synthesis of
D -serine, this would seem to be a particularly relevant area of
investigation in regards to the function and physiology of the
NMDA receptor.
One very important facet of the study of the human enzyme
that is missing is a complete picture of its structure which would
aid in any conclusions about its mechanism that might be made
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